整合肿瘤信息的升级版PRECISE-DAPT肿瘤评分用于急性心肌梗死后出血风险预测
本研究基于英国MINAP与HES APC登记数据库构建2005年1月1日至2019年3月31日ST段抬高型心肌梗死患者全国联动队列,将肿瘤作为二分类变量加入PRECISE-DAPT评分,构建改良评分并与原评分比较1年大出血预测效能,结果显示改良评分可提高区分度并使绝大多数肿瘤患者归为高出血风险。
要点
- 改良评分使94.0%的肿瘤患者归为高出血风险,无肿瘤患者归为低或极低出血风险。
核心结论
- 将肿瘤加入PRECISE-DAPT评分可使多数肿瘤患者被识别为高出血风险,并提高区分度,同时不削弱在无肿瘤患者中的表现。
研究设计与样本
- 基于英国Myocardial Ischaemia National Audit Project与Hospital Episode Statistics Admitted Patient Care登记数据库的全国联动队列。
- 纳入2005年1月1日至2019年3月31日ST段抬高型心肌梗死患者,共216 709例,其中4569例患肿瘤。
- 主要结局为1年大出血。
- 采用Cox回归模型将肿瘤作为二分类变量加入PRECISE-DAPT评分生成改良评分,并与原评分比较效能。
主要发现
- 改良评分高、中、低、极低出血风险类别的出血率分别为6.3%、3.8%、2.9%、2.2%。
- 按原评分,65.5%的肿瘤患者为高出血风险,21.6%为低或极低出血风险;按改良评分,94.0%的肿瘤患者为高出血风险,6.0%为中出血风险,无肿瘤患者归为低或极低出血风险。
临床怎么用
- 对急性心肌梗死患者使用整合肿瘤信息的改良PRECISE-DAPT评分,有助于将多数合并肿瘤者识别为高出血风险并指导出血风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This study assessed the impact of incorporating cancer as a predictor on performance of the PRECISE-DAPT score. METHODS: A nationally linked cohort of ST-elevation myocardial infarction patients between 1 January 2005 and 31 March 2019 was derived from the UK Myocardial Ischaemia National Audit Project and the UK Hospital Episode Statistics Admitted Patient Care registries. The primary outcome was major bleeding at 1 year. A new modified score was generated by adding cancer as a binary variable to the PRECISE-DAPT score using a Cox regression model and compared its performance to the original PRECISE-DAPT score. RESULTS: A total of 216 709 ST-elevation myocardial infarction patients were included, of which 4569 had cancer. The original score showed moderate accuracy (C-statistic .60), and the modified score showed modestly higher discrimination (C-statistics .64; hazard ratio 1.03, 95% confidence interval 1.03-1.04) even in patients without cancer (C-statistics .63; hazard ratio 1.03, 95% confidence interval 1.03-1.04). The net reclassification index was .07. The bleeding rates of the modified score risk categories (high, moderate, low, and very low bleeding risk) were 6.3%, 3.8%, 2.9%, and 2.2%, respectively. According to the original score, 65.5% of cancer patients were classified as high bleeding risk (HBR) and 21.6% were low or very low bleeding risk. According to the modified score, 94.0% of cancer patients were HBR, 6.0% were moderate bleeding risk, and no cancer patient was classified as low or very low bleeding risk. CONCLUSIONS: Adding cancer to the PRECISE-DAPT score identifies the majority of patients with cancer as HBR and can improve its discrimination ability without undermining its performance in patients without cancer.
引用
- Dafaalla, Costa, Kontopantelis, et al. Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score. Eur Heart J. 2024. PMID: 39016180. doi:10.1093/eurheartj/ehae463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。